Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Immunoglobulin Preparations

Immunoglobulin preparations are produced from human blood and contain a number of quite different antibodies (polyclonal antibodies).

Search results 1 to 25 from a total of 71

Name De­scrip­tion Mar­ket­ing Au­tho­ri­sa­tion Hold­er Li­cense Num­ber Li­cense Date Use Further Information

UMAN BIG

Humanes Hepatitis-B-Immunglobulin

Kedrion S.p.A.

PEI.H.04324.01.1 12.02.2010 intramuskulär

Tetagam P

Tetanus-Ig

CSL Behring GmbH

108a/89 22.09.1992 intramuskulär

Rhesonativ

Anti-D-Ig

Octapharma GmbH

PEI.H.03287.01.1 20.03.2006 intramuskulär

Berirab

Tollwut-Ig

CSL Behring GmbH

107a/89 22.09.1992 intramuskulär

Hepatitis-B-Immunglobulin Behring

Hepatitis-B-Ig

CSL Behring GmbH

105a/89 22.09.1992 intramuskulär

Rhophylac 300 Mikrogramm/2 ml, Injektionslösung in einer Fertigspritze

Anti-D (Rh) Immunglobulin vom Menschen

Orifarm GmbH

PEI.H.11819.01.1 24.04.2017 intramuskulär, intravenös

Rhophylac 300

Anti-D (Rh) Immunglobulin

EurimPharm Arzneimittel GmbH

PEI.H.11955.01.1 09.05.2018 intramuskulär, intravenös

Rhophylac 200

Anti-D Immunglobulin vom Menschen

CSL Behring GmbH

PEI.H.00399.03.1 05.11.2009 intramuskulär, intravenös

Rhophylac 300

Anti-D (Rh) Immunglobulin

CC-Pharma GmbH

PEI.H.11959.01.1 05.03.2018 intramuskulär, intravenös

Rhophylac 300

Anti-D (Rh) Immunglobulin

kohlpharma GmbH

PEI.H.11931.01.1 23.06.2017 intramuskulär, intravenös

Rhophylac 300

Anti-D (Rh) Immunglobulin

EMRA-MED Arzneimittel GmbH

PEI.H.11954.01.1 30.01.2019 intramuskulär, intravenös

Rhophylac 300

Anti-D (Rh) Immunglobulin

Abacus Medicine A/S

PEI.H.12036.01.1 29.04.2020 intramuskulär, intravenös

Rhophylac 300 Mikrogramm / 2 ml

Anti-D Immunglobulin aus Plasma von menschlichen Spendern

AxiCorp Pharma GmbH

PEI.H.12050.01.1 19.08.2020 intramuskulär, intravenös

Rhophylac 300

Anti-D-Ig

CSL Behring GmbH

PEI.H.00399.02.1 15.03.2001 intramuskulär, intravenös

Fovepta 200 I.E.

Humanes Hepatitis-B-Immunglobulin

Biotest Pharma GmbH

PEI.H.11536.01.1 28.03.2012 intramuskulär, subkutan

Octagam 5%

Normales Immunglobulin vom Menschen (IVIg)

EMRA-MED Arzneimittel GmbH

PEI.H.12047.01.1 01.10.2020 intravenös

VENBIG

Humanes Hepatitis-B-Immunglobulin

Kedrion S.p.A.

PEI.H.04266.01.1 17.08.2009 intravenös

Intratect 50 g/l

Immunglobulin vom Menschen zur intravenösen Anwendung

EurimPharm Arzneimittel GmbH

PEI.H.11455.01.1 18.01.2013 intravenös

Octagam 5%

Normales Immunglobulin vom Menschen (IVIg)

kohlpharma GmbH

PEI.H.11856.01.1 05.06.2017 intravenös

Cytotect CP Biotest

Cytomegalie-Ig

Biotest Pharma GmbH

6a/96 07.01.2000 intravenös

Intratect

Normales Immunglobulin vom Menschen

Biotest Pharma GmbH

PEI.H.02901.01.1 27.09.2004 intravenös

Intratect 50 g/l, Infusionslösung

Immunglobulin vom Menschen

Kohlpharma GmbH

PEI.H.11720.01.1 25.03.2015 intravenös

Gamunex 10%

Normales Immunglobulin vom Menschen (IVIg)

EMRA-MED Arzneimittel GmbH

PEI.H.11926.01.1 29.05.2019 intravenös

Octagam 5%

Normales Immunglobulin vom Menschen (IVIg)

Orifarm GmbH

PEI.H.11746.01.1 05.03.2018 intravenös

Biseko

Humanes Normal­serumpräparat

Biotest Pharma GmbH

32a/78 01.08.1980 intravenös

Disclaimer

The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.

The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.

As of: PEI announcement No. 518 in BAnz AT 26.06.2024 B7.

Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)

Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.

If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.

Updated: 26.06.2024